.: Yondelis . Results Phase IV STS : The Median Progression-Free Survival Was 5.9 Months, with 70 and 49% of Patients Free from Progression at 3 and 6 Months after Treatment, Respectively. "" Three (1.4%) Patients Achieved a Complete Response "" and 55 (25.2%) Patients Achieved a Partial Response for an Objective Response Rate of 26.6%.

CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE Y PASAMOS DEL VIAL DE 4 Mg AI VIAL DE 2 Mg .//. JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES...EN ESPAÑA NO SE HAN ENTERADO AÚN...SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .

25 octubre 2017

Yondelis . Results Phase IV STS : The Median Progression-Free Survival Was 5.9 Months, with 70 and 49% of Patients Free from Progression at 3 and 6 Months after Treatment, Respectively. "" Three (1.4%) Patients Achieved a Complete Response "" and 55 (25.2%) Patients Achieved a Partial Response for an Objective Response Rate of 26.6%.

The scientific magazine “Anti-cancer drugs” i has published the results of the Y-IMAGE Phase IV study .

In real-life, Yondelis® improves the results obtained in previous clinical trials in soft tissue sarcoma.

 Yondelis® provides in this observational study (Y-IMAGE) in the treatment of soft tissue sarcoma, an overall survival of 21.3 months, this being higher that the 13.5 months observed in a recently approved compound for this indication .

 With regards to progression free survival, in this study Yondelis® reached 5.9 months improving the 4.6 months of another recently approved drug for this indication .